BiotechTube

Infliximab

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Mar 1, 2012 → May 1, 2013

NCT ID
NCT01571206

About Infliximab

Infliximab is a phase 1 stage product being developed by Celltrion for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01571206. Target conditions include Ankylosing Spondylitis.

What happened to similar drugs?

20 of 20 similar drugs in Ankylosing Spondylitis were approved

Approved (20) Terminated (4) Active (0)
✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
✅GolimumabJohnson & JohnsonApproved
✅AdalimumabAbbVieApproved
✅InfliximabMerckApproved
✅GolimumabMerckApproved
✅RemicadeMerckApproved
✅RemicadeMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04922827Phase 2Completed
NCT01571219Phase 3Completed
NCT01571206Phase 1Completed
NCT01220518Phase 1Completed
NCT01217086Phase 3Completed

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
29
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
adalimumabEisaiPhase 3
40
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
32
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
35
Golimumab + PlaceboJohnson & JohnsonPhase 3
40
GolimumabJohnson & JohnsonApproved
43
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
38
placebo for risankizumab + risankizumabAbbViePhase 2
35
AdalimumabAbbVieApproved
39
Upadacitinib + PlaceboAbbViePhase 2
35
AdalimumabAbbViePre-clinical
26
infliximab + PlaceboMerckPhase 3
40
InfliximabMerckApproved
35
Infliximab + Placebo + NaproxenMerckPhase 3
40
InfliximabMerckPre-clinical
26
GolimumabMerckApproved
43
RemicadeMerckApproved
43
RemicadeMerckApproved
43
InfliximabMerckApproved
43